1. "Oxford University Press"
  2. "Adilia Hormigo"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (2)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (12)
  2. Biostatistics Service (7)
  3. Epidemiology and Biostatistics (7)
  4. Population Sciences Research Program (7)
  5. Surgery (6)
  6. GSK Faculty (4)

More Groups

People
  1. Adilia Hormigo (17)
  2. Lisa De Angelis (12)
  3. Lauren Abrey (8)
  4. Andrew Lassman (7)
  5. Katherine Panageas (7)
  6. Eric Holland (6)

More People

Years
  1. 2013 (1)
  2. 2011 (4)
  3. 2008 (3)
  4. 2007 (3)
  5. 2006 (3)
  6. 2005 (2)

More Years

Publications
  1. Neuro-Oncology (17)
Publishers
  1. Oxford University Press (17)

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Journal Article

    Omuro, A.; Chan, T. A.; Abrey, L. E.; Khasraw, M.; Reiner, A. S.; Kaley, T. J.; De Angelis, L. M.; Lassman, A. B.; Nolan, C. P.; Gavrilovic, I. T.; more...
    Neuro-Oncology (2013)

    Fulltext@MSK | Save
  • Phase I trial of temsirolimus and perifosine for recurrent or progressive malignant glioma
    Meeting Abstract

    Lassman, A. B.; Kaley, T. J.; Deangelis, L. M.; Hormigo, A.; Mellinghoff, I. K.; Otap, D. D.; Seger, J.; Doyle, L. A.; Ludwig, E.; Lacouture, M. E.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of dasatinib in target selected patients with recurrent glioblastoma (RTOG 0627)
    Meeting Abstract

    Lassman, A. B.; Wang, M. H.; Gilbert, M. R.; Aldape, K. D.; Beumer, J. J.; Wright, J.; Takebe, N.; Puduvalli, V. K.; Hormigo, A.; Gaur, R.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma
    Meeting Abstract

    Omuro, A.; Beal, K.; Correa, D.; Chan, T.; DeAngelis, L.; Gavrilovic, I.; Nolan, C.; Hormigo, A.; Lassman, A. B.; Kaley, T.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Journal Article

    Iwamoto, F. M.; Hottinger, A. F.; Karimi, S.; Riedel, E.; Dantis, J.; Jahdi, M.; Panageas, K. S.; Lassman, A. B.; Abrey, L. E.; Fleisher, M.; more...
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Meeting Abstract

    Ney, D.; DeAngelis, L.; Nolan, C.; Gavrilovic, I.; Hormigo, A.; Lassman, A.; Abrey, L.
    Neuro-Oncology (2008)

    Fulltext@MSK | Save
  • Ykl-40 and matrix metalloproteinase-9 (Mmp-9) as serum tumor markers in gliomas
    Meeting Abstract

    Iwamoto, F.; Hottinger, A.; Jahdi, M.; Dantis, J.; Karimi, S.; Riedel, E.; Panageas, K.; Gu, B.; Rao, J.; Fleisher, M.; more...
    Neuro-Oncology (2008)

    Fulltext@MSK | Save
  • Cd133+expression in the brain and high-grade glioma of a mouse model with a lacz reporter knock-in at the Cd133 locus
    Meeting Abstract

    Hormigo, A.; Shmelkov, S.; Hooper, A.; Butler, J.; James, D.; Hambardzumyan, D.; Becher, O.; Holland, E. C.; Rafii, S.
    Neuro-Oncology (2008)

    Fulltext@MSK | Save
  • Long-term safety and steroid-sparing potential of corticorelin acetate injection for treatment of peritumoral brain edema: Third interim report of an open-label study as part of a phase III program
    Meeting Abstract

    Recht, L.; Mechtler, L.; Alksne, J.; Arenson, E.; Paleologos, N.; Avgeropoulos, N.; Hormigo, A.; Perry, J.; Raizer, J.; Robins, H. I.; more...
    Neuro-Oncology (2007)

    Fulltext@MSK | Save
  • A phase II trial of temozolomide and vinorelbine for patients with recurrent brain metastases
    Meeting Abstract

    Iwamoto, F.; Omuro, A.; Raizer, J.; Nolan, C.; Hormigo, A.; Gavrilovic, I.; Abrey, L.
    Neuro-Oncology (2007)

    Fulltext@MSK | Save